US 12,123,876 B2
Antibody binding to HEG1 and use of the antibody for detection and treatment of mesothelioma
Shoutaro Tsuji, Toyko (JP); Taihei Kageyama, Toyko (JP); Kota Washimi, Tokyo (JP); Makiko Tsuji, Tokyo (JP); Rieko Matsuura, Toyko (JP); Mitsuyo Yoshihara, Yokohama (JP); and Kohzoh Imai, Tokyo (JP)
Assigned to Kanagawa Prefectural Hospital Organization, Yokohama (JP); and The University of Tokyo, Tokyo (JP)
Appl. No. 16/077,911
Filed by Kanagawa Prefectural Hospital Organization, Yokohama (JP); and The University of Tokyo, Tokyo (JP)
PCT Filed Jan. 16, 2017, PCT No. PCT/JP2017/001250
§ 371(c)(1), (2) Date Aug. 14, 2018,
PCT Pub. No. WO2017/141604, PCT Pub. Date Aug. 24, 2017.
Claims priority of application No. 2016-025689 (JP), filed on Feb. 15, 2016.
Prior Publication US 2019/0071517 A1, Mar. 7, 2019
Int. Cl. G01N 33/574 (2006.01); A61K 39/395 (2006.01); A61K 49/00 (2006.01); A61K 49/16 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); C12N 15/09 (2006.01); C12N 15/62 (2006.01); G01N 33/577 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/574 (2013.01) [A61K 39/395 (2013.01); A61K 49/00 (2013.01); A61K 49/0058 (2013.01); A61K 49/16 (2013.01); A61P 35/00 (2018.01); C07K 14/705 (2013.01); C07K 16/30 (2013.01); C07K 16/3092 (2013.01); C07K 16/46 (2013.01); C12N 15/09 (2013.01); C12N 15/62 (2013.01); G01N 33/57423 (2013.01); G01N 33/68 (2013.01)] 5 Claims
 
1. A monoclonal antibody that binds to HEG1 protein having O-glycosylation having sialylation obtained from mesothelioma or HEG1 protein on a cell membrane of mesothelioma, or an antigen-binding fragment thereof, wherein the antibody and the antigen-binding fragment each comprise a heavy chain variable region comprising a CDR1 having the amino acid sequence set forth in SEQ ID NO: 6, a CDR2 having the amino acid sequence set forth in SEQ ID NO:8, and a CDR3 having the amino acid sequence set forth in SEQ ID NO: 10, and a light chain variable region comprising a CDR1 having the amino acid sequence set forth in SEQ ID NO: 12, a CDR2 having the amino acid sequence set forth in SEQ ID NO: 14, and a CDR3 having the amino acid sequence set forth in SEQ ID NO: 16.